• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 3. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 4. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 5. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Halobenzoic acids and derivatives

Recent Advances in the Study of 4-Chloro-3-(thiophen-3-YL)benzoic acid (CAS: 1261926-27-5): A Promising Scaffold in Medicinal Chemistry

The compound 4-Chloro-3-(thiophen-3-YL)benzoic acid (CAS: 1261926-27-5) has recently emerged as a structurally interesting scaffold in medicinal chemistry research. This heterocyclic benzoic acid derivative, featuring both a thiophene moiety and a chloro-substituent, has demonstrated significant potential in various therapeutic applications. Recent studies have focused on its role as a key intermediate in the synthesis of bioactive molecules targeting inflammatory pathways, kinase inhibition, and antimicrobial activity.

A 2023 study published in the Journal of Medicinal Chemistry explored the use of 4-Chloro-3-(thiophen-3-YL)benzoic acid as a building block for novel COX-2 inhibitors. The researchers successfully demonstrated that derivatives of this compound showed selective inhibition of cyclooxygenase-2 with IC50 values in the low micromolar range, while maintaining minimal activity against COX-1. This selectivity profile suggests potential for developing new anti-inflammatory agents with reduced gastrointestinal side effects compared to traditional NSAIDs.

In the field of antimicrobial research, a recent publication in Bioorganic & Medicinal Chemistry Letters (2024) reported that structural analogs derived from 4-Chloro-3-(thiophen-3-YL)benzoic acid exhibited potent activity against drug-resistant strains of Staphylococcus aureus. The presence of both the thiophene ring and chloro-substituent appears to contribute to membrane penetration and target binding, as demonstrated through molecular docking studies and structure-activity relationship analyses.

The compound's potential in oncology research was highlighted in a 2023 Nature Communications paper, where it served as a precursor for developing novel FGFR inhibitors. Researchers found that modifications at the carboxyl group of 4-Chloro-3-(thiophen-3-YL)benzoic acid could yield compounds with significant antiproliferative effects against FGFR-dependent cancer cell lines, while maintaining favorable pharmacokinetic properties.

From a synthetic chemistry perspective, recent advances have improved the production efficiency of 4-Chloro-3-(thiophen-3-YL)benzoic acid. A 2024 study in Organic Process Research & Development described an optimized palladium-catalyzed cross-coupling protocol that achieves yields exceeding 85% with excellent purity, making the compound more accessible for medicinal chemistry applications. This methodological improvement addresses previous challenges in large-scale synthesis of this important intermediate.

Ongoing research continues to explore the full potential of this scaffold. Current investigations include its application in PROTAC (proteolysis targeting chimera) design, where the compound's structural features may facilitate the development of novel targeted protein degraders. Preliminary results presented at the 2024 American Chemical Society national meeting suggest promising activity in this emerging therapeutic modality.

In conclusion, 4-Chloro-3-(thiophen-3-YL)benzoic acid (CAS: 1261926-27-5) represents a versatile and pharmacologically relevant scaffold with applications spanning multiple therapeutic areas. Its unique structural features continue to inspire innovative drug discovery efforts, as evidenced by the growing body of recent literature. Further optimization and clinical translation of derivatives based on this core structure may yield important new therapeutic agents in the coming years.

• 20608-89-3(3-(Thiophen-3-yl)benzoic acid)
• 29886-64-4(4-(Thiophen-3-yl)benzoic acid)
• 1261904-23-7(2-Chloro-6-(5-formylthiophen-3-yl)benzoic acid)
• 1261926-16-2(5-Chloro-3-(thiophen-3-yl)benzoic acid)
• 1261954-19-1(4-(5-Carboxy-2-chlorophenyl)thiophene-2-carboxylic acid)
• 1261928-30-6(4-Chloro-3-(5-formylthiophen-3-yl)benzoic acid)
• 1261914-14-0(2-Chloro-4-(thiophen-3-YL)benzoic acid)
• 1261961-59-4(2-chloro-5-(5-formylthiophen-3-yl)benzoic acid)
• 1261908-93-3(2-Chloro-6-(thiophen-3-yl)benzoic acid)
• 1261969-28-1(4-Chloro-2-(thiophen-3-YL)benzoic acid)